SIRT3 and fatty liver disease: Theacrine ameliorated acylcarnitine metabolism disorder in high-fat diet (HFD)-fed mice, resulting in suppression of hepatic steatosis and liver inflammation and improvement of energy expenditure through the SIRT3/LCAD signaling pathway (35).